Trials / Unknown
UnknownNCT00100074
To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1
Safety and Tolerability Study of Sublingual Lobeline
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (planned)
- Sponsor
- National Institute on Drug Abuse (NIDA) · NIH
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To assess the safety and tolerability of 7.5, 15 and 30 mg of sublingual lobeline.
Detailed description
The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lobeline |
Timeline
- Start date
- 2004-09-01
- Completion
- 2005-04-01
- First posted
- 2004-12-23
- Last updated
- 2017-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00100074. Inclusion in this directory is not an endorsement.